The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  • Email Email
  • Glossary Glossary

Low risk to complete all 28 days?

Nov 10, 2013

Hi doc, my little boy accidentilly stepped on a syringe needle in a park. We know this is low risk, but the doctor still put him on a 28 day course of lamivudine, zidovudine and aluvia. It is quite a struggle to get him to take his meds daily and we are now on day 23 and he has had enough. Will the pep be less affective if we stop early or only give him the lamivudine and zidovudine? The aluvia seems to be the big struggle. Thank you

Response from Dr. Young

Hello and thanks for posting.

While Aluvia (Kaletra) is recommended in some post-exposure prophylaxis (PEP) protocols, it's not always. Indeed, many occupational PEP regimens only recommend the use of NRTI combinations, such as Combivir or Truvada.

Bearing this in mind, and recognizing that your son has already taken more than three weeks of the Combivir+Kaletra, given his difficulties, I think that it would be reasonable to stop the Aluvia for the remainder of his treatment.

Hope that helps, BY

chenge kaletra to nevirapina

  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint